Alainn Clinic - Logo

Tirzepatide

Learn How Tirzepatide Helps With Diabetic Control And Weight Loss

tirzepatide injection header

Benefits

Tirzepatide is a once-weekly injectable prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. In addition to that, tirzepatide has also shown great efficacy in weight management while improving cardiovascular and metabolic risks including blood pressure, waist circumference and cholesterol.

tirzepatide benefits

What Is Tirzepatide

Tirzepatide is a new, first-in-class molecule with combined synergistic action on both GIP and GLP-1 receptors (‘Twincretin’) to help control blood glucose levels in patients with type 2 diabetes mellitus as well as help in weight management in the overweight or obese.

Chemical structure of tirzepatide

How Does It Work

Tirzepatide functions by binding to GIP and GLP-1 receptors, imitating the natural functions of natural GIP and GLP-1 hormones, typically released in our intestines after a meal. While GIP stimulates insulin secretion and inhibits gastric secretion activity, GLP-1 reduces appetite, slows gastric emptying, increases insulin secretion and inhibits glucagon release. Synergistically, there is compounded effectiveness which gives rise to the desired effects of better blood glucose control and body weight reduction.

tirzepatide how

Active Ingredient

Tirzepatide is the key component (active ingredient) in both Mounjaro and Zepbound, which delivers its therapeutic effects. In the following sections, we’ll explore how Tirzepatide’s unique properties make Mounjaro effective for certain health conditions and how it similarly contributes to the efficacy of Zepbound.

What Is Mounjaro

Mounjaro, developed by Eli Lilly and Company, is the brand name for the drug Tirzepatide, specifically designed and approved for the treatment of type 2 diabetes. As the first and only glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it represents a significant advancement in glucose management for diabetic patients

mounjaro image

What is Zepbound

Zepbound, recently approved by the FDA in November 2023 and also a product of Eli Lilly and Company, represents another brand name for the drug Tirzepatide. Differing from Mounjaro, Zepbound is specifically indicated for chronic weight management in adults with obesity or overweight. This approval covers its use alongside a reduced-calorie diet and increased physical activity, expanding the therapeutic scope of Tirzepatide.

zepbound image

Who Is It For

Tirzepatide is ideally suited for adults with type 2 diabetes who have not achieved adequate blood sugar control through diet, exercise, or other antidiabetic medications. It is particularly beneficial for those with an increased risk of cardiovascular and metabolic conditions. In its formulation as Zepbound, Tirzepatide is indicated for chronic weight management in adults with obesity or overweight.

tirzepatide candidate 1

Side Effects

As with most medications, there are potential side effects of Mounjaro and Zepbound. The most common side effects encountered are nausea, diarrhoea, vomiting, constipation and abdominal discomfort. These effects are typically temporary, most pronounced during the dose-escalation period and may diminish over time. It is crucial to consult with your doctor about any side effects experienced.

Tips to manage GLP-1 receptor agonist-based medications side effects. Learn more.

” I was at a pre-diabetes stage at one point, and by modifying my cravings for local Malaysian food, combining this with regular, easy exercise, and following a supervised weight loss medication plan, I’ve achieved my weight loss goal. Here’s my story and practical tips” – Intan

Results

tirzepatide results glucose level

Glucose level: Tirzepatide has demonstrated effectiveness in clinical trials for reducing HbA1c levels, a proxy for blood sugar control. In the SURPASS-1 trial published in The Lancet, patients treated with Mounjaro experienced superior glycaemic control compared to those on placebo. The trial reported reductions in HbA1c levels over 40 weeks ranging from -1.87% to -2.07% depending on Tirzepatide dosage compared to placebo (+0.04%) (P<0.0001).

tirzepatide weight reductions chart

Weight management: In the SURMOUNT-1 study published in The New England Journal of Medicine, Tirzepatide has shown to provide substantial and sustained reductions in body weight and waist circumference, further supporting its multifaceted treatment outcomes. Subcutaneously administered Tirzepatide at doses of 5mg, 10mg and 15mg resulted in weight loss of -15%, -19.5% and -20.9% respectively over a period of 72 weeks, far exceeding weight loss parameters of those on placebo (-3.1%).

Sustainable Results

To achieve the best results with Tirzepatide, it is imperative to use it as directed by your doctor. This includes maintaining a healthy diet, engaging in regular exercise and performing regular blood sugar monitoring (for diabetic patients). Furthermore, it is crucial to have ongoing medical supervision throughout the course of your treatment. Your doctor should be equipped to assist with any necessary adjustments to your treatment plan and monitor for potential side effects. This personalised attention can significantly enhance the safety and effectiveness of your treatment with Mounjaro or Zepbound.

tirzepatide sustainable

Contraindications

Tirzepatide should be avoided in patients with personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. It should also be avoided in patients with known allergic reactions to any of the ingredients in Mounjaro/Zepbound.

tirzepatide contra indication

Mounjaro In Malaysia

Mounjaro (Tirzepatide) was approved by the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia for use as a prescription medication since August 2023. Patients looking to use Mounjaro must first undergo a thorough medical evaluation or consultation with a doctor to determine its suitability for their condition.
UPDATE (March 2024): Due to worldwide shortage, Mounjaro is estimated to be available in Malaysia during Q3/Q4 2024.

Managing Weight Without Type 2 Diabetes

For individuals who are overweight or obese but have not been diagnosed with type 2 diabetes, managing weight effectively is still a paramount concern for overall health and well-being.
There are FDA and NPRA approved medications available that can aid in weight management for those without diabetes.
One option to consider is Saxenda (Liraglutide), a medication that can regulate appetite and lead to reduced food intake. Another alternative is Contrave (Naltrexone/Bupropion), which combines the actions of two different medications to influence the brain’s behaviour towards food and appetite

FAQs

Mounjaro (Tirzepatide) is primarily indicated for the treatment of diabetes. While weight loss is a synergistic effect of taking Mounjaro, it is important to note that it is not approved as a weight-loss medication for individuals without type 2 diabetes.
However, there are instances where Tirzepatide has been used off-label for the treatment of obesity under certain caveats. It is essential to understand that such usage is unique and determined on a case-by-case basis, underscoring the importance of professional medical consultations.

It is essential to disclose and discuss your full medical history with your doctor prior to starting Mounjaro. Some health conditions may affect how Mounjaro works or increase the risk of side effects.

Mounjaro starts working soon after administration, but it takes several weeks to arrive at the optimal and full effects of the medication, namely better glucose control, weight reduction and cardiovascular risk mitigation.

Mounjaro is a combined GIP and GLP-1 receptor agonist while Ozempic is a GLP-1 receptor agonist. They both mimic the GLP-1 hormone and are used in the treatment of type 2 diabetes. However, Mounjaro is a distinct, first-in-class medication which incorporates GIP agonism, augmenting the effects of insulin secretion, glucagon suppression and appetite reduction. Both medications are once-weekly injectables, but individual results and side effects may vary.

Research suggests that Mounjaro is generally safe for long-term use, under the supervision of a qualified healthcare professional. Regular follow-ups and clinical monitoring are essential to ensure continued efficacy and to address any emerging concerns.

While Zepbound is U.S. FDA approved for use in chronic weight management, it has yet to be approved by Malaysia’s NPRA. The future approval and availability of Zepbound in Malaysia remain uncertain at this time. Please revisit for further updates.

” I was at a pre-diabetes stage at one point, and by modifying my cravings for local Malaysian food, combining this with regular, easy exercise, and following a supervised weight loss medication plan, I’ve achieved my weight loss goal. Here’s my story and practical tips“. – Intan